The role of small airways in obstructive airway diseases

European Respiratory Review

Volumn 20, Issue 119, 2011, Pages 23-33

  Burgel, P R ^a  

^a Université Paris Descartes ^*  (France)

Author keywords

Airway inflammation; Airway remodelling; Alveoli; Asthma; Bronchioles; Chronic obstructive pulmonary disease

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; UNCLASSIFIED DRUG;

AIRWAY REMODELING; AIRWAY RESISTANCE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL FEATURE; DRUG EFFICACY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INFLAMMATORY INFILTRATE; INTEGRATIVE MEDICINE; LUNG EMPHYSEMA; LUNG FUNCTION TEST; LUNG MECHANICS; MATHEMATICAL MODEL; MEDICAL RESEARCH; NETHERLANDS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; RESPIRATORY EPITHELIUM; REVIEW; SMALL AIRWAY DISEASE; SYMPOSIUM;

AIRWAY REMODELING; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CONGRESSES AS TOPIC; DIAGNOSTIC IMAGING; HUMANS; LUNG; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 79952430815     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00010410     Document Type: Review

References (92)

1. Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 1992; 72: 1016-1023.
2. Burgel P-R, de Blic J, Chanez P, et al. Update on the roles of distal airways in asthma. Eur Respir Rev 2009; 18: 80-95.
3. Aikawa T, Shimura S, Sasaki H, et al. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992; 101: 916-921.
4. Dunnill MS. The pathology of asthma with special reference to changes in the bronchial mucosa. J Clin Pathol 1960; 13: 27-33.
5. Kuyper LM, Pare PD, Hogg JC, et al. Characterization of airway plugging in fatal asthma. Am J Med 2003; 115: 6-11.
6. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997; 10: 292-300.
7. Dolhnikoff M, da Silva LF, de Araujo BB, et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J Allergy Clin Immunol 2009; 123: 1090-1097.
8. de Magalhaes Simoes S, dos Santos MA, da Silva Oliveira M, et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy 2005; 35: 602-611.
9. Shiang C, Mauad T, Senhorini A, et al. Pulmonary periarterial inflammation in fatal asthma. Clin Exp Allergy 2009; 39: 1499-1507.
10. Mauad T, Silva LF, Santos MA, et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004; 170: 857-862.
11. de Medeiros Matsushita M, da Silva LF, dos Santos MA, et al. Airway proteoglycans are differentially altered in fatal asthma. J Pathol 2005; 207: 102-110.
12. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100: 44-51.
13. Minshall EM, Hogg JC, Hamid QA. Cytokine mRNA expression in asthma is not restricted to the large airways. J Allergy Clin Immunol 1998; 101: 386-390.
14. Taha RA, Minshall EM, Miotto D, et al. Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and nonasthmatic individuals. J Allergy Clin Immunol 1999; 103: 476-483.
15. Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 2002; 20: 254-259.
16. Kraft M, Martin RJ, Wilson S, et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999; 159: 228-234.
17. Saetta M, Ghezzo H, Kim WD, et al. Loss of alveolar attachments in smokers. A morphometric correlate of lung function impairment. Am Rev Respir Dis 1985; 132: 894-900.
18. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277-1281.
19. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
20. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717.
21. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-826.
22. Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-1409.
23. Chrysofakis G, Tzanakis N, Kyriakoy D, et al. Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest 2004; 125: 71-76.
24. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
25. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. An animal model of autoimmune emphysema. Am J Respir Crit Care Med 2005; 171: 734-742.
26. Motz GT, Eppert BL, Wesselkamper SC, et al. Chronic cigarette smoke exposure generates pathogenic T cells capable of driving COPD-like disease in Rag2-/- mice. Am J Respir Crit Care Med 2010; 181: 1223-1233.
27. Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567-569.
28. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, et al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 156-163.
29. Cottin V, Fabien N, Khouatra C, et al. Anti-elastin autoantibodies are not present in combined pulmonary fibrosis and emphysema. Eur Respir J 2009; 33: 219-221.
30. Greene CM, Low TB, O'Neill SJ, et al. Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. Am J Respir Crit Care Med 2010; 181: 31-35.
31. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010; 5: e8578.
32. Macklem PT, Mead J. Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol 1967; 22: 395-401.
33. Bates JH, Suki B. Assessment of peripheral lung mechanics. Respir Physiol Neurobiol 2008; 163: 54-63.
34. Battaglia S, den Hertog H, Timmers MC, et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005; 60: 639-644.
35. Tsoukias NM, George SC. A two-compartment modelofpulmonary nitric oxide exchange dynamics. J Appl Physiol 1998; 85: 653-666.
36. van Veen IH, Sterk PJ, Schot R, et al. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 2006; 27: 951-956.
37. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224.
38. I'nt Veen JC, Beekman AJ, Bel EH, et al. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000; 161: 1902-1906.
39. Muskulus M, Slats AM, Sterk PJ, et al. Fluctuations and determinism of respiratory impedance in asthma and chronic obstructive pulmonary disease. J Appl Physiol 2010; 109: 1582-1591.
40. Fens N, Zwinderman AH, van der Schee MP, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2009; 180: 1076-1082.
41. Bourdin A, Paganin F, Prefaut C, et al. Nitrogen washout slope in poorly controlled asthma. Allergy 2006; 61: 85-89.
42. van Veen IH, Ten Brinke A, Sterk PJ, et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008; 32: 344-349.
43. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-1360.
44. Stanescu D, Sanna A, Veriter C, et al. Identification of smokers susceptible to development of chronic airflow limitation: a 13-year follow-up. Chest 1998; 114: 416-425.
45. O'Donnell DE, Laveneziana P, Ora J, et al. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax 2009; 64: 216-223.
46. Dellaca RL, Pompilio PP, Walker PP, et al. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J 2009; 33: 1329-1337.
47. Wagner EM, Liu MC, Weinmann GG, et al. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990; 141: 584-588.
48. Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104: 394-403.
49. McFadden ER Jr, Kiker R, Holmes B, et al. Small airway disease. An assessment of the tests of peripheral airway function. Am J Med 1974; 57: 171-182.
50. Dutrieue B, Vanholsbeeck F, Verbanck S, et al. A human acinar structure for simulation of realistic alveolar plateau slopes. J Appl Physiol 2000; 89: 1859-1867.
51. Verbanck S, Paiva M. Model simulations of gas mixing and ventilation distribution in the human lung. J Appl Physiol 1990; 69: 2269-2279.
52. Verbanck S, Schuermans D, Van Muylem A, et al. Ventilation distribution during histamine provocation. J Appl Physiol 1997; 83: 1907-1916.
53. Verbanck S, Schuermans D, Paiva M, et al. The functional benefit of anti-inflammatory aerosols in the lung periphery. J Allergy Clin Immunol 2006; 118: 340-346.
54. Verbanck S, Schuermans D, Vincken W. Inflammation and airway function in the lung periphery of patients with stable asthma. J Allergy Clin Immunol 2010; 125: 611-616.
55. Verbanck S, Schuermans D, Paiva M, et al. Small airway function improvement after smoking cessation in smokers without airway obstruction. Am J Respir Crit Care Med 2006; 174: 853-857.
56. Laurent F, Latrabe V, Raherison C, et al. Functional significance of air trapping detected in moderate asthma. Eur Radiol 2000; 10: 1404-1410.
57. Goldin JG, McNitt-Gray MF, Sorenson SM, et al. Airway hyperreactivity: assessment with helical thin-section CT. Radiology 1998; 208: 321-329.
58. Beigelman-Aubry C, Capderou A, Grenier PA, et al. Mild intermittent asthma: CT assessment of bronchial cross-sectional area and lung attenuation at controlled lung volume. Radiology 2002; 223: 181-187.
59. Ueda T, Niimi A, Matsumoto H, et al. Role of small airways in asthma: investigation using high-resolution computed tomography. J Allergy Clin Immunol 2006; 118: 1019-1025.
60. Mitsunobu F, Ashida K, Hosaki Y, et al. Decreased computed tomographic lung density during exacerbation of asthma. Eur Respir J 2003; 22: 106-112.
61. Tunon-de-Lara JM, Laurent F, Giraud V, et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J Allergy Clin Immunol 2007; 119: 583-590.
62. Akira M, Toyokawa K, Inoue Y, et al. Quantitative CT in chronic obstructive pulmonary disease: inspiratory and expiratory assessment. AJR Am J Roentgenol 2009; 192: 267-272.
63. Matsuoka S, Kurihara Y, Yagihashi K, et al. Airway dimensions at inspiratory and expiratory multisection CT in chronic obstructive pulmonary disease: correlation with airflow limitation. Radiology 2008; 248: 1042-1049.
64. van Beek EJ, Dahmen AM, Stavngaard T, et al. Hyperpolarised 3He MRI versus HRCT in COPD and normal volunteers: PHIL trial. Eur Respir J 2009; 34: 1311-1321.
65. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844.
66. Leach C, Colice GL, Luskin A. Particle size of inhaled corticoster-oids: does it matter? J Allergy Clin Immunol 2009; 124: Suppl. 6, S88-S93.
67. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215-1222.
68. Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipro-pionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999; 104: S258-S267.
69. Juniper EF, Price DB, Stampone PA, et al. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121: 1824-1832.
70. Papi A, Paggiaro PL, Nicolini G, et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007; 29: 682-689.
71. Papi A, Paggiaro P, Nicolini G, et al. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62: 1182-1188.
72. Scichilone N, Battaglia S, Soriano C, et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy 2010; 65: 897-902.
73. Huchon G, Magnussen H, Chuchalin A, et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009; 103: 41-49.
74. Sturton RG, Trifilieff A, Nicholson AG, et al. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008; 324: 270-275.
75. Devolder A, De Backer L, Vos W, et al. Evaluation of the acute bronchodilator effect of beclomethasone/formoterol fixed combination on central and peripheral airway dimensions in asthmatic patients. Eur Respir J 2009; 34: Suppl. 53, 518s.
76. Cohen J, Postma DS, Douma WR, et al. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J 2010; [Epub ahead of print DOI: 10.1183/?09031936.00204109].
77. Contoli M, Baraldo S, Marku B, et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol 2010; 125: 830-837.
78. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
79. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
80. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.
81. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-943.
82. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009; 151: 517-527.
83. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
84. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
85. Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-1639.
86. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-548.
87. De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/ formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010; 23: 137-148.
88. John M, Bosse S, Oltmanns U, et al. Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir Med 2005; 99: 1418-1424.
89. Tatsis G, Kotsifas K, Filaditaki V, et al. Efficacy of beclomethasone dipropionate HFA 200 microg once daily in chronic obstructive pulmonary disease and bronchial asthma. J Int Med Res 2007; 35: 361-373.
90. Watz H, Breithecker A, Rau WS, et al. Micro-CT of the human lung: imaging of alveoli and virtual endoscopy of an alveolar duct in a normal lung and in a lung with centrilobular emphysema - initial observations. Radiology 2005; 236: 1053-1058.
91. Hogg JC, McDonough JE, Sanchez PG, et al. Micro-computed tomography measurements of peripheral lung pathology in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6: 546-549.
92. Auffray C, Adcock IM, Chung KF, et al. An integrative systems biology approach to understanding pulmonary diseases. Chest 2010; 137: 1410-1416.